X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the partnership, EDDC will apply its expertise in therapeutic protein design and antibody engineering to develop these novel TCR-based bispecific molecules for the treatments for solid tumors.
Lead Product(s): TCR-based Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Experimental Drug Development Centre
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership December 21, 2023
Details:
ImmunoScape’s Deep Immunomics and machine learning platforms comprise a highly effective method for the discovery of T-cell receptor (TCR) candidates, targeting novel antigens such as cancer-specific shared splice variants and human endogenous retroviral elements.
Lead Product(s): TCR-T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Anzu Partners
Deal Size: $14.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 20, 2022
Details:
The licensing deal will allow ImmunoScape to pursue TCR-T therapeutics using this library, and accelerate identification of novel T cell receptors for therapeutic development.
Lead Product(s): TCR-T Therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Pure MHC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 16, 2022
Details:
Valo Tx, will use its proprietary PeptiVAX technology to coat a spike-expressing adenoviral vector vaccine with HLA-restricted peptides. These peptides may be associated with a clinically beneficial T cell immune responses to Sars-CoV-2's highly conserved genes.
Lead Product(s): Peptide based-pan Coronavirus vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Valo Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
